• Skip to primary navigation
  • Skip to main content
Kinderhook Industries

Kinderhook Industries

  • Investment Philosophy
  • Team
  • Our Portfolio
  • Portfolio News
  • LP Portal

Kinderhook Sells StudyKik to Syneos Health

Kinderhook Sells StudyKik to Syneos Health

September 15, 2021

New York, NY – Kinderhook Industries, LLC (“Kinderhook”) announced today the sale of StudyKIK (“StudyKIK” or the “Company”) to Syneos Health (NYSE: SYNH). Financial terms of the transaction were not disclosed.

Launched in 2014 as a global network of patient-focused communities, StudyKIK and its technology platform have demonstrated improved quality and accelerated enrollment timelines in certain clinical trials by up to 94% and reduced enrollment start-up times by up to 75%. In addition, StudyKIK provides eConsent, telemedicine video calling, phone pre-qualifications, and patient retention application solutions. The company manages over 1,000 indication-specific patient community groups and has enrolled more than 5,400 protocols supporting over 3,800 research sites across the globe. The platform encompasses more than 6 million patients through social media, speeding access to patients who traditionally would not have participated in clinical trials.

“StudyKIK was built to serve as a disruptive solution to the status quo in the patient recruitment industry and accelerate the clinical trial process to get new treatments to people as fast and as safely as possible,” said Matt Miller, Chief Executive Officer of StudyKIK. “We are thrilled by this outcome and are excited to continue fulfilling our mission as part of the Syneos family. We are also grateful for Kinderhook’s partnership over the past few years. Kinderhook has provided us with both the financial support and strategic guidance that have been instrumental in accelerating our growth and enabling our success.”

Chris Michalik, Managing Director at Kinderhook, stated, “This is a great outcome for Kinderhook, StudyKIK and its employees.  We are very proud of the accomplishments of the StudyKIK team, led by Matt Miller, and we expect the Company to continue to flourish as part of Syneos.”

“We are thankful to have had the opportunity to partner with Matt Miller and work with the amazing team at StudyKIK”, said Michael Zoch, Managing Director of Kinderhook.  “Kinderhook’s investment in StudyKIK highlights the key tenets of Kinderhook’s investment strategy – partnering with world class management teams to grow businesses in niche markets.”

Kirkland & Ellis served as legal counsel to StudyKIK and Latham & Watkins provided legal counsel to Syneos in the transaction.

For additional information about this transaction, please contact: 
Christian Michalik
Managing Director
(212) 201-6782
[email protected]
 
Michael Zoch
Managing Director
(212) 201-6785
[email protected]


About Kinderhook Industries

Founded in 2003, Kinderhook Industries, LLC is a private investment firm that has raised $8.5 billion of committed capital. We have made in excess of 500 investments and follow-on acquisitions since inception. Kinderhook’s investment philosophy is predicated on matching differentiated, growth-oriented investment opportunities with financial expertise and our proprietary network of operating partners. Our focus is on middle market businesses with defensible niche market positioning in the healthcare services, environmental & industrial services, and light manufacturing & automotive sectors.

For more information, please visit https://www.kinderhook.com


About StudyKIK

StudyKIK is a patient recruitment and retention technology company that was founded on building patient communities to increase awareness for clinical trials. Servicing over 3,600 research sites, StudyKIK supports patient recruitment, patient retention, eConsent solutions, telemedicine video calling, and study companion mobile applications to expedite clinical trials. They have addressed the clinical trial patient recruitment & retention problem by building the technology solutions needed for research sites and pharmaceutical companies to access, manage, and communicate with high-quality patients in real-time.

For more information, please visit http://www.studykik.com


About Syneos Health

Syneos Health (Nasdaq:SYNH) is the only fully integrated biopharmaceutical solutions organization. Syneos, which includes a Contract Research Organization (CRO) and Contract Commercial Organization (CCO), is purpose-built to accelerate customer performance to address modern market realities. Syneos brings together approximately 27,000 clinical and commercial minds with the ability to support customers in more than 110 countries. Syneos shares insights, uses the latest technologies and applies advanced business practices to speed its customers’ delivery of important therapies to patients.

For more information, please visit https://www.syneoshealth.com/

Copyright © 2025 Kinderhook Industries. All rights reserved.